Katsuki Masahito, Matsumori Yasuhiko, Ichihara Taisuke, Yamada Yuya, Kawamura Shin, Kashiwagi Kenta, Koh Akihito, Goto Tetsuya, Kaneko Kazuma, Wada Naomichi, Yamagishi Fuminori
Department of Neurosurgery, Suwa Red Cross Hospital, Suwa 392-0027, Japan.
Headache Outpatient, Suwa Red Cross Hospital, Suwa 392-0027, Japan.
Life (Basel). 2024 Jan 8;14(1):96. doi: 10.3390/life14010096.
To investigate the prescription patterns for patients aged 6-17 years with headaches in the REZULT database.
We cross-sectionally investigated (Study 1) the pattern of prescription and the proportion of triptan overprescription (≥30 tablets/90 d of triptans) among patients diagnosed with headaches in 2020. Next, we longitudinally studied patients (Study 2) for more than two years from the initial headache diagnosis (July 2010 to April 2022). The number of prescribed tablets was counted every 90 days.
In Study 1, headache diagnoses were assigned to 62,568 of 543,628 (11.51%) patients, and 1524 of 62,568 (2.44%) patients received acute medication. Single nonsteroidal anti-inflammatory drugs and triptans were prescribed to 620/624 (99.36%) and 5/624 (0.80%) of patients aged 6-11 years, respectively, and 827/900 (91.89%) and 91/900 (10.11%) of patients aged 12-17 years, respectively. Triptan overprescription was observed in 11/96 (11.46%) patients, and 5/11 (45.45%) of those patients received prophylactic medication. In Study 2, 80,756/845,470 (9.55%) patients aged 6-17 years were diagnosed with headaches that persisted for at least two years. Over two years, 44/80,756 (0.05%) patients were overprescribed triptans, and 3408/80,756 (4.22%) patients were prescribed prophylaxis on at least one occasion.
Based on real-world data, the appropriate use of prophylactic treatment is still problematic. Overprescription of triptans was observed, although the number of patients was small.
在REZULT数据库中研究6至17岁头痛患者的处方模式。
我们进行了横断面调查(研究1),调查2020年被诊断为头痛的患者的处方模式以及曲坦类药物过度处方(≥30片/90天的曲坦类药物)的比例。接下来,我们对从初始头痛诊断起(2010年7月至2022年4月)超过两年的患者进行了纵向研究(研究2)。每90天统计一次处方片剂的数量。
在研究1中,543,628名患者中有62,568名(11.51%)被诊断为头痛,62,568名患者中有1524名(2.44%)接受了急性药物治疗。6至11岁患者中,分别有620/624(99.36%)和5/624(0.80%)的患者开具了单一非甾体抗炎药和曲坦类药物,12至17岁患者中,分别有827/900(91.89%)和91/900(10.11%)的患者开具了单一非甾体抗炎药和曲坦类药物。在96名患者中有11名(11.46%)观察到曲坦类药物过度处方,其中5/11(45.45%)的患者接受了预防性药物治疗。在研究2中,845,470名6至17岁患者中有80,756名(9.55%)被诊断为头痛且持续至少两年。在两年多的时间里,80,756名患者中有44名(0.05%)被过度开具曲坦类药物,80,756名患者中有3408名(4.22%)至少有一次接受了预防性药物治疗。
基于真实世界数据,预防性治疗的合理使用仍然存在问题。尽管患者数量较少,但仍观察到曲坦类药物的过度处方。